Patients with Amanita phalloides-induced liver failure (LF) have a high mortality, despite significant advances in intensive care managemet. Our study evaluated the effect of Molecular Absorbents Recirculating System (MARS) comparative with optimal intensive care (OIC) in adults with this condition, in the absence of liver transplantation (LT). Six consecutive patients (women, range 16—61 years) affected by A.phalloides-induced LF were treated with OIC (3 patients) and MARS (3 patients). Laboratory parameters and hepeatic encephalopaty were evaluated 15 min before and 24 hours following each MARS treatment. Three 6-hour sessions per patient were performed in MARS group, with a statistically significant decrease in ammonia (p value 0.011), alaninaminotransferase (ALT) and prothrombin time (PT) (p value 0.004). Two patients had a significant rebound in bilirubin (+116%; p value 0. 04) 24 hours following MARS. Mortality in MARS group was 66.7%. Survival rate in OIC was 0%. Negative prognostic markers: lack of PT and hepatic encephalopaty improvement, rebound in bilirubin, and delay of MARS therapy initiation. No significant adverse reactions occurred during MARS. MARS is an effective depurative therapy in adults with A.phalloides-induced LF, but alone is not enough. Survival is predicted by the results of the initial MARS, amount of mushroom consumed, and time from toxin exposure.
Tan HKMolecular adsorbent recirculating system (MARS). Ann Acad Med Singapore2004; 33: 329-335.
2.
Sherlock S., Dooley J.Diseases of the liver and biliary system. 9th edn. Oxford: Blackwell Scientific Publications , 1993.
3.
Novelli G., et al. MARS (molecular adsorbent recirculating system): experience in 34 cases of acute liver failure. Liver2002; 22: 43-47.
4.
Covic A., et al. Successful use of molecular absorbent regenerating system (MARS) dialysis for the treatment of fulminant hepatic failure in children accidentally poisoned by toxic mushroom ingestion. Liver Int2003; 23: 21-27.
5.
Lionte C., Hurjui J., Teleman S.Hypoglycemia in acute mushrooms poisoning. Rev Med Chir Soc Med Nat Iasi2004; 108: 281-285.
6.
Stange J., et al. Liver support by extracorporeal blood purification: a clinical observation. Liver Transpl2000; 6: 603-613.
Donnelly M., Wax P.Cyclopeptide-containing mushrooms: the deadly amanita mushrooms. In: Brent J, Wallace K, Burkhart K, Phillips S, Ward Donovan J (eds) Critical care toxicology: diagnosis and management of the critically poisoned patient. Philadelphia: Elsevier Mosby, 2005 : 127. 7-1286.
9.
Lionte C., et al. Clinical, morphological and therapeutic aspects in acute poisoning with Amanita Phalloides. Ther Pharmacol Clin Toxicol2002; VI: 9-16.
10.
Aji DY, et al. Haemoperfusion in Amanita phalloides poisoning. J Trop Pediatr1995; 41: 371-374.
11.
Scheurlen C. , et al. Amanita phalloides intoxications in a family of russian immigrants. Case reports and review of the literature with a focus on orthotopic liver transplantation. Zeitschrift für Gastroenterologie1994; 32: 399-404.
12.
Rubik J., et al. Successful treatment of a child with fulminant liver failure and coma caused by Amanita phalloides intoxication with albumin dialysis without liver transplantation. Pediatr Transpl2004 ; 8: 295-300.
13.
Wu BF, Wang MMMolecular adsorbent recirculating system in dealing with maternal Amanita poisoning during the second pregnancy trimester: a case report. Hepatobiliary Pancreat Dis Int2004; 3: 152-154.
14.
Catalina MV, et al. Liver failure due to mushroom poisoning: clinical course and new treatment perspectives. Gastroenterol Hepatol2003; 26: 417-420.
15.
Shi Y., et al. MARS: optimistic therapy method in fulminant hepatic failure secondary to cytotoxic mushroom poisoning - a case report. Liver2002; 22: 78-80.
16.
Lionte C., Sorodoc L., Simionescu V.Successful treatment of an adult with Amanita phalloides-induced fulminant liver failure with Molecular Adsorbent Recirculating System (MARS). Rom J Gastroenterol2005; 14: 267-271.
17.
Sein Anand J., Chodorowski Z., Wiśniewski M., Waldman W.The assessment of albumin liver dialysis - MARS efficacy in the treatment of Amanita phalloides poisoning. Przegl Lek2007; 64: 255-257.
18.
Sein Anand J., Chodorowsk Z., Hydzik P.Molecular adsorbent recirculating system - MARS as a bridge to liver transplantation in amanita phalloides intoxication . Przegl Lek2005; 62: 480-481.
19.
Hydzik P., et al. Liver albumin dialysis (MARS) - treatment of choice in Amanita phalloides poisoning?Przegl Lek2005; 62: 475-479.
20.
Stange J., Mitzner S.A carrier-mediated transport of toxins in a hybrid membrane. Safety barrier between a patient"s blood and a bioartificial liver. Int J Artif Organs1996; 19: 677-691.
21.
Stange J., et al. Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif Organs1999; 23: 319-330.
22.
Mitzner SR, et al. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J Am Soc Nephrol2001; 12: S75-S82.
23.
Lamesch P., et al. Molecular adsorbents recirculating system in patients with liver failure. Transpl Proc2001; 33: 3480-3482.
24.
Pugh RN, et al. Transection of the oesophagus for bleeding oesophageal varices . Br J Surg1973; 60: 646-649.
25.
Kamath PS, et al. A model to predict survival in patients with end-stage liver disease. Hepatology2001; 33: 464-470.
26.
Jalan R., et al. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J Hepatol2003; 38: 24-31.
27.
Faulstich H.New aspects of Amanita poisoning. Klin Wochenschr1979; 57: 1143-1152.
28.
Himmelmann A., Mang G., Schnorf-Huber S.Lethal ingestion of stored Amanita phalloides mushrooms. Swiss Med Wkly2001; 131: 616-617.
29.
Vesconi S., et al. Therapy of cytotoxic mushroom intoxication. Crit Care Med1985; 13: 402-406.
30.
Christen Y. , Minazio P., de Moerloose P.Monitoring of haemostatic parameters in five cases of Amanita phalloides poisoning. Blood Coagul Fibrinolysis1993; 4: 627-630.
31.
Zawadzki J. , Jankowska I., Moszczynska A., Januszewicz P.Hypouricemia due to increased tubular secretion of urate in children with Amanita phalloides poisoning. Nephron1993; 65: 375-380.
32.
O’Brien BL, Khuu L.A fatal Sunday brunch: Amanita mushroom poisoning in a Gulf Coast family. Am J Gastroenterol1996; 91: 581-583.
33.
Rahman T., Hodgson H.Clinical management of acute hepatic failure. Intensive Care Med2001; 27: 467-476.
34.
Stockmann HB , Ijzermans JNProspects for the temporary treatment of acute liver failure. Eur J Gastroenterol Hepatol2002; 14: 195-203.
35.
Bernuau J., Benhamou JPFulminant and subfulminant hepatic failure. In: McIntyre N, Benhamou JP, Bircher J, Rizzetto M, Rodes J, editors. Oxford Textbook of Clinical Hepatology. Volume 2. 1st edn. Oxford: Oxford Univ Press, 1991.
36.
Mitzner SR, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial . Liver Transpl2000; 6: 277-286.
37.
Jalan R., Sen S., Williams R.Prospects for extracorporeal liver support. Gut2004; 53: 890-898.
38.
Steiner C., Mitzner S.Experiences with MARS liver support therapy in liver failure: analysis of 176 patients of the International MARS Registry. Liver2002; 22: 20-25.
39.
Awad SS, et al. Results of a phase I trial evaluating a liver support device utilizing albumin dialysis. Surgery2001; 130: 354-362.
40.
Jalan R., Williams R.Improvement of cerebral perfusion after MARS therapy: Further clues about the pathogenesis of hepatic encephalopathy?Liver Transpl2001; 7: 713-715.
41.
Kreymann B., et al. Albumin dialysis: effective removal of copper in a patient with fulminant Wilson disease and successful bridging to liver transplantation: a new possibility for the elimination of protein-bound toxins. J Hepatology1999; 31: 1080-1085.
42.
Kapoor D., Williams R., Jalan R.MARS: a new treatment for hepatorenal failure. Molecular adsorbent and recirculating system. Gastroenterology2000; 119: 1799-1800.
43.
Mitzner S., et al. Improvement of multiple organ functions in hepatorenal syndrome during albumin dialysis with the molecular adsorbent recirculating system . Ther Apher2001; 5: 417-422.
44.
Kellersmann R., et al. Application of molecular adsorbent recirculating system in patients with severe liver failure after hepatic resection or transplantation: initial single-centre experiences. Liver2002; 22: 56-58.
45.
Sorkine P., et al. Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure. Crit Care Med2001; 29: 1332-1336.
46.
Voiculescu M., et al. Successful application of MARS therapy in a 7 year-old patient with hepatic chronic rejection and severe cholestatic syndrome. Rom J Gastroenterol2002; 11: 135-140.
47.
Escudié L., et al. Amanita phalloides poisoning: reassessment of prognostic factors and indications for emergency liver transplantation . J Hepatol2007; 46: 466-473.
48.
Faybik P., et al. Extracorporeal albumin dialysis in patients with Amanita phalloides poisoning. Liver Int2003; 23: 28-33.
49.
Kantola T., et al. Early molecular adsorbents recirculating system treatment of Amanita mushroom poisoning. Ther Apher Dial2009; 13: 399-403.
50.
Sein Anand J., Chodorowski Z., Wiśniewski M., Waldman W.The assessment of albumin liver dialysis-MARS efficacy in the treatment of Amanita phalloides poisoning. Przegl Lek2007; 64: 255-257.
51.
Hydzik P., et al. Liver albumin dialysis (MARS) - treatment of choice in Amanita phalloides poisoning?Przegl Lek2005; 62: 475-479.
